Relmada Therapeutics Inc (RLMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 11,334 | 9,776 | 3,497 | 1,385 | 1,353 |
| Marketable Securities | 206,397 | 224,187 | 89,510 | 12,502 | 19,266 |
| Receivables | 11 | N/A | N/A | N/A | N/A |
| TOTAL | $219,040 | $235,343 | $93,984 | $14,854 | $21,094 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 20 | 20 | 20 | 22 | 22 |
| TOTAL | $20 | $20 | $20 | $22 | $22 |
| Total Assets | $219,059 | $235,363 | $94,004 | $14,876 | $21,116 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,409 | 5,731 | 1,569 | 1,453 | 1,362 |
| Accrued Expenses | 5,012 | 7,160 | 4,862 | 3,737 | 3,773 |
| TOTAL | $7,421 | $12,892 | $6,431 | $5,190 | $5,135 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 5,080 | 3,739 | 1,061 | 221 | 32 |
| TOTAL | $5,080 | $3,739 | $1,061 | $221 | $32 |
| Total Liabilities | $12,501 | $16,630 | $7,492 | $5,411 | $5,167 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 106,670 | 104,890 | 104,890 | 73,334 | 33,192 |
| Common Shares | 107 | 105 | 73 | 33 | 33 |
| Retained earnings | -730,233 | -717,319 | -698,267 | -678,399 | -668,308 |
| TOTAL | $206,558 | $218,733 | $86,512 | $9,466 | $15,950 |
| Total Liabilities And Equity | $219,059 | $235,363 | $94,004 | $14,876 | $21,116 |